[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Rani Therapeutics Holdings Inc Cl A (RANI)

Rani Therapeutics Holdings Inc Cl A (RANI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 82,989
  • Shares Outstanding, K 123,883
  • Annual Sales, $ 1,630 K
  • Annual Income, $ -29,670 K
  • EBIT $ -35 M
  • EBITDA $ -34 M
  • 60-Month Beta 0.78
  • Price/Sales 51.36
  • Price/Cash Flow N/A
  • Price/Book 2.36
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.41
  • Most Recent Earnings $-0.04 on 05/15/26
  • Next Earnings Date 08/06/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 242.23% (-351.51%)
  • Historical Volatility 58.59%
  • IV Percentile 22%
  • IV Rank 19.54%
  • IV High 938.91% on 08/12/25
  • IV Low 73.08% on 09/09/25
  • Expected Move (DTE 35) 0.0000 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 399
  • Volume Avg (30-Day) 71
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 7,229
  • Open Int (30-Day) 6,738
  • Expected Range 0.6973 to 0.6973

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.05
  • Number of Estimates 1
  • High Estimate $-0.05
  • Low Estimate $-0.05
  • Prior Year $-0.18
  • Growth Rate Est. (year over year) +72.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6126 +13.83%
on 07/13/26
0.8325 -16.24%
on 06/22/26
-0.0679 (-8.87%)
since 06/17/26
3-Month
0.6126 +13.83%
on 07/13/26
1.1400 -38.83%
on 05/14/26
-0.2591 (-27.09%)
since 04/17/26
52-Week
0.4010 +73.89%
on 07/21/25
3.8700 -81.98%
on 10/22/25
+0.2804 (+67.26%)
since 07/17/25

Most Recent Stories

More News
Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

RT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of PG-102 No adverse events attributed to RaniPill Capsule; treatment-related adverse events were mild...

RANI : 0.6973 (+4.09%)
Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates

~ Collaboration will leverage the RaniPill® platform to explore oral delivery of PegBio's proprietary portfolio of novel obesity and metabolic disease molecules ~ ~ Agreement expands Rani's obesity...

RANI : 0.6973 (+4.09%)
Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer

SAN JOSE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”; “Rani” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company...

RANI : 0.6973 (+4.09%)
Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules

SAN JOSE, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...

RANI : 0.6973 (+4.09%)
Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition

- Continued advancement of the ongoing Phase 1 study of RT-114 via RaniPill® for the treatment of obesity in collaboration with ProGen – - Appointed Alireza Javadi, Ph.D. as Chief Technical Officer...

RANI : 0.6973 (+4.09%)
Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference

SAN JOSE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...

RANI : 0.6973 (+4.09%)
Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy

SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...

RANI : 0.6973 (+4.09%)
Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update

- Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed $60.3 million oversubscribed private placement led by Samsara BioCapital...

RANI : 0.6973 (+4.09%)
Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization

SAN JOSE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...

RANI : 0.6973 (+4.09%)
Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results

SAN JOSE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...

RANI : 0.6973 (+4.09%)

Business Summary

Rani Therapeutics Holdings Inc. is a clinical stage biotherapeutics company. It focused on advancing technologies to enable the development of orally administered biologics. Rani Therapeutics Holdings Inc. is based in SAN JOSE, Calif.

See More

Key Turning Points

3rd Resistance Point 0.8117
2nd Resistance Point 0.7703
1st Resistance Point 0.7338
Last Price 0.6973
1st Support Level 0.6559
2nd Support Level 0.6145
3rd Support Level 0.5780

See More

52-Week High 3.8700
Fibonacci 61.8% 2.5448
Fibonacci 50% 2.1355
Fibonacci 38.2% 1.7262
Last Price 0.6973
52-Week Low 0.4010

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.